New antibody AP601 enters human trials for Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase study is testing a new drug called AP601 in 36 people with advanced solid tumors that have not responded to standard treatments. AP601 is a bispecific antibody designed to target a protein called CD73 found on some cancer cells. The main goal is to find the safes…
Phase: PHASE1 • Sponsor: AP Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC